Quarterly Activities/Appendix 4C Cash Flow Report
Released
Released
Announcement PDF
20 July 2023
Quarterly Activity Report and Appendix 4C
Doctor Care Anywhere Group PLC (ASX:DOC, “Doctor Care Anywhere” or “the Company”) is
pleased to provide an update on trading and corporate activity for the quarter ended 30 June
2023 (“Q2 2023”)1.
Executive Summary
•
•
•
•
•
•
•
•
Annualised revenue run rate guidance for 1H23 of £42-£46m met
Successful launch of Mixed Clinical Workforce proposition to drive margin expansion and
provide additional capacity for growth
Continued focus on core UK business with sale of Australian subsidiary GP2U (completed
in early July 2023)
190,800 consultations delivered, up 32.1% on PcP and up 3.4% QoQ
Total Operating and Investing Outflows materially reduced in the quarter as the business
drives to profitability. Total Operating and Investing Outflows were £2.3m/A$4.4m in Q2
2023, down £2.1m/A$4.1m v Q2 2022 and £1.7m/A$$3.2m v Q1 2023
Exited quarter with £6.2m / A$11.9m cash on hand. This has been further enhanced in Q3
2023 with the final £2.5m of loan drawn down under the AXA loan agreement that is
expected to see the business through to profitability.
UK Board restructure completed with the appointment of Non-Executive Director Dr
Aleksandra Spencer in July 2023
Reiterating previous guidance of:
o Gross margin of 50-55% by 2H23
o Contribution margin of 35-40% by 2H23
o Positive EBITDA by Q1 2024
Operational Performance – Key KPIs
Eligible Lives at Period End
Activated Lives3 at Period End
Consultations4 in Period
Secondary Care Journeys5 in Period
Repeat Patients6 in Period
2
Actual
% increase /
(decrease) on
% increase /
(decrease) on
Q2 2023
000’s
2,836.7
965.5
190.8
10.5
140.8
Q2 2022 (PCP)
Q1 2023 (QoQ)
12.3%
27.7%
32.1%
45.8%
35.4%
3.1%
4.6%
3.4%
6.1%
13.3%
This Quarterly Activity Report and Appendix 4C is prepared in GBP in accordance with International
Financial Reporting Standards in conformity with the requirements of the Companies Act 2006 (UK) and is
unaudited. Figures expressed in Australian Dollars (“A$”) have been converted from British Pounds Sterling
at an exchange rate of AUD:GBP 1:0.52 for the quarter ended 30 June 2023 and at 1:0.53 for the quarter ended
30 June 2022.
2
Eligible Lives represents the total number of people who have an entitlement to use DOC’s services.
3
Activated Lives represents the total number of people who “sign up” for DOC’s service and enter their
personal details.
4
Consultations is the number of GP, ANP, Psychiatrist and Psychologist consultations delivered to patients
over the period.
5
Secondary Care Journeys is the number of secondary care journeys completed by patients over the period
following a referral from an initial GP or ANP consultation on the DCA platform.
6
Repeat Patients represents the number of consultations completed by patients who had previously
completed an appointment.
1
1|Page
Commentary
Eligible Lives at the end of Q2 2023 were 2.8 million, up 12.3% on PcP and 3.1% QoQ. Growth in
Eligible Lives was primarily driven by further penetration of the Company’s services across
existing channel partners.
At the end of Q2 2023, Activated Lives were 965,500, up 27.7% on the PcP and 4.6% QoQ. Growth
in Activated Lives continued to be higher than the growth in Eligible lives. Growth in Activated
Lives was driven by marketing and engagement activities across the Company’s expanded pool
of Eligible Lives.
Consultation volumes continued to grow year-on-year, with 190,800 consultations delivered in Q2
2023, up 32.1% on PcP and 3.4% QoQ. The increase in consultation volumes was driven by
successful initiatives to increase GP supply in the period, on-going growth in demand for our
services, and the successful launch of the Mixed Clinical Workforce proposition in June which
resulted in the highest quarterly volume of consultations to date.
Consultations by Quarter (000’s)
First Time
Repeat
185
143
152
151
165
146
117
91
53
63
25
35
28
28
89
74
42
32
93
102
104
104
51
50
47
41
76
53
55
38
34
41
192
124
141
60
51
118
47
Q2 2020 Q3 2020 Q4 2020 Q1 2021 Q2 2021 Q3 2021 Q4 2021 Q1 2022 Q2 2022 Q3 2022 Q4 2022 Q1 2023 Q2 2023
Returning patients represented 73% of all consultations in the quarter, an increase of 4
percentage points compared to the PcP and an increase of 6 percentage points against the prior
quarter. The volume of returning patients increased by 35% from the PcP and by 13% QoQ,
demonstrating patient satisfaction with the service.
2|Page
Cash Position: Progress to Profitability and Net Cash Generation
Q2
2023
Q1 2023
Cash movements
£000
Receipts from customers
Q2 2022
£000
% increase
/(decrease)
QoQ
£000
% increase
/(decrease)
versus PcP
10,111
8,245
22.6%
8,731
15.8%
Other/Non-operating staff costs
(2,337)
(2,293)
1.9%
(2,989)
(21.8%)
R&D/Intellectual property costs
(1,343)
(1,529)
(12.2%)
(2,702)
(50.3%)
Operating costs
(7,168)
(6,378)
12.4%
(5,557)
29.0%
Other administrative costs
(1,683)
(2,639)
(36.2%)
(2,131)
(21.0%)
143
649
(78%)
234
(38.9%)
(2,277)
(3,944)
(42.3%)
(4,414)
(48.4%)
Financing cash flows
(258)
7,342
n/m
(134)
92.5%
Exchange gain/(loss)
(16)
(10)
(60.0%)
(7)
128.6%
(2,551)
3,388
-
(4,555)
-
Other inflows
Total operating and investing outflows
Net cash flow
The Company is making positive strides towards cash breakeven in Q1 2024, with total operating
and investing cash outflows reducing by £1.6 million (A$3.1 million) QoQ and by £2.1 million (A$4.0
million) versus PCP. This was driven by growth and cost reduction activity. Most notably
•
•
•
•
•
Cash receipts from customers increased by 22.6% QoQ with the increase driven by
increased appointment volumes, a contractual inflationary increase in our price per
consultation received from AXA, and a large receipt from a subscription revenue
customer. This also represents a 15.8% increase versus PcP driven by the same factors.
Staff cash spend increased by 1.9% QoQ as an annual salary increase in April was offset by
headcount reductions, and reduced by 21.8% versus PcP, primarily driven by cost savings
from reduced headcount following the restructuring programme in 1H 22. This is in spite
of substantial growth in the business.
R&D and intellectual property cash spend reduced 12.2% QoQ and 50.3% vs PcP which is
primarily from the restructuring programme in 1H 22 which reduced the size of the
technology development team.
Operating cash spend increased 12.4% QoQ and 29.0% vs PcP, primarily driven by
increases in consultation volumes in both instances.
Other administrative costs cash spend decreased by 36.2% QoQ and by 21% vs PcP. The
QoQ variance is primarily due to the timing of several large annual payments in the
previous quarter such as our annual insurance premiums. The reduced costs vs PcP are
primarily due to the restructuring programme performed in 1H22 which reduced
headcount across multiple departments.
Other cash inflows in Q2 2023 and Q2 2022 relate to VAT receipts in the period, with Q1 2023 also
including an R&D tax rebate.
Net financing cash outflows for the quarter were £0.3 million (A$0.6 million), a change of £7.6
million (A$14.5 million) from the net inflow in the prior quarter, which included the £7.5m drawn
down under the AXA loan facility. Net cash outflows from financing activities in Q2 2022 were £0.1
million (A$0.3 million) which was due to the timing of lease payments.
3|Page
The overall cash outflow for the business in Q2 2023 was £2.5 million (A$4.8 million), down by £5.9
million (A$11.2 million) from Q1 2023 largely due to the financing from the AXA loan facility
received in the prior period. The cash outflow was £2.0m lower (A$3.8 million) than Q2 2022 due
to revenue growth and cost savings across the business.
The Company exited the quarter with £6.2 million (A$11.8 million) of cash on hand as at 30 June
2023. It also had a further £2.5m (A$4.8 million) available under the AXA loan agreement which
was drawn down in July 2023.
Activities since previous market update
Following the market update issued as part of the Appendix 4C release on 26 April 2023, an
update is provided below on key matters:
Operational and financial
-
-
Successful launch of the Company’s Mixed Clinical Workforce proposition in mid-June
2023, increasing DCA’s capacity to serve patients, and reducing DCA’s cost to serve. Total
consultations in June were 66,000, of which over 8,000 appointments were provided by
our ANPs, demonstrating a quick uptake for the new service.
Tranche 3 of the AXA loan (£2.5million /A$4.8million) drawn down in July 2023 following
achievement of conditions precedent. DCA has now fully drawn down the facility which
is expected to see the Company through to breakeven in Q1 2024.
Completion of sale of Australian subsidiary GP2U to My Emergency Doctor (MED) in July
2023 for A$3.0m, comprising A$2.5m worth of unlisted ordinary shares in MED and $0.5m
of cash, adjusted for normalised working capital.
Appointment to the Board of Dr Aleksandra Spencer as an independent Non-Executive
Director and chair of the Company’s Audit and Risk Management Committee.
The sale of GP2U and appointment of Dr Spencer are in line with the Company’s strategic
aim to focus on the UK market.
Guidance
-
-
DCA is pleased to announce that it has met its annualised revenue run rate target for 1H23
end of £42-£46m.
In calculating the run rate, the Company calculated the revenue earned from the launch
of MCW (14 June 2023) to 30 June 2023 and pro-rated for a calendar year. Management
deems this to be reflective of the revised model which DCA now operates and therefore a
fair indication of annualised run rate at the end of the reporting period. Management also
notes that Q3 2023 run rate is likely to be lower, in line with normal UK seasonal trends.
As at the date of this report, DCA is on track to meet the remainder of its guidance issued
in February 2023 (summarised below, and subject to the assumptions and dependencies
accompanying that guidance).
Metric
Guidance
Gross margin of 50-55%
Contribution margin of 35-40%
EBITDA positive
To be achieved in 2H23
To be achieved in 2H23
Achieved in Q1 2024
Other
As required by ASX Listing Rule 4.7C.3, the Company discloses that payments to related parties
in the period totalled £0.09 million, representing payment of Director Fees to Non-Executive
4|Page
Directors (including pension and payroll tax payments), a decrease of £0.25 million on the prior
quarter, which included one-off payments.
This update must be read as a whole and is subject to the disclaimer that it:
•
•
•
Is subject to the assumptions referred to above and, if any of those assumptions are not
met, actual results may differ from this guidance;
Is not a prediction or guarantee of future performance; and
Involves known and unknown risks, uncertainties and other factors which are beyond the
Company’s control, and which may cause actual results to differ from this guidance. The
Company is not liable for the accuracy and/or correctness of this information and any
differences between the guidance and actual outcomes.
Corporate Overview
•
•
•
•
366,771,846 shares in issue
Market capitalisation of A$19.4m at date of report release
£6.2m (A$11.8m) cash at 30 June 2023
£7.5m (A$13.9m) in drawn down debt at 30 June 2023
- ENDS -
This ASX announcement has been authorised for release by the Board of Directors.
About Doctor Care Anywhere:
Doctor Care Anywhere Group PLC is the UK’s largest private provider of telehealth services. The
Company works with insurers, healthcare providers and corporate customers to connect
patients to a range of digitally-enabled telehealth services on its proprietary platform. It is
committed to delivering the best possible patient experience and clinical care through digitally
enabled, joined up, evidence-based pathways on its proprietary platform.
5|Page
Appendix 4C
Quarterly report for entities subject to Listing Rule 4.7B
Name of entity
Doctor Care Anywhere Group PLC
ARBN
Quarter ended (“current quarter”)
645 163 873
30 June 2023
Consolidated statement of cash flows
1.
Cash flows from operating activities
1.1
Receipts from customers
1.2
Payments for
Current quarter
£’000
Year to date
(6 months)
£’000
10,111
18,356
(592)
(1,302)
(7,167)
(13,545)
(77)
(152)
-
-
(e) staff costs
(2,337)
(4,630)
(f) administration and corporate costs
(1,536)
(4,045)
(a) research and development
(b) product manufacturing and operating
costs
(c) advertising and marketing
(d) leased assets
1.3
Dividends received (see note 3)
-
-
1.4
Interest received
5
7
1.5
Interest and other costs of finance paid
-
(1)
1.6
Income taxes paid
-
-
1.7
Government grants and tax incentives
-
196
1.8
Other (provide details if material)
139
592
1.9
Net cash from / (used in) operating
activities
(1,454)
(4,524)
2.
Cash flows from investing activities
2.1
Payments to acquire or for:
(a) entities
-
-
(b) businesses
-
-
(72)
(128)
-
-
(751)
(1,570)
(c) property, plant and equipment
(d) investments
(e) intellectual property
6|Page
Consolidated statement of cash flows
(f) other non-current assets
Current quarter
£’000
Year to date
(6 months)
£’000
-
-
(g) entities
-
-
(h) businesses
-
-
(i) property, plant and equipment
-
-
(j) investments
-
-
(k) intellectual property
-
-
(l) other non-current assets
-
-
2.3
Cash flows from loans to other entities
-
-
2.4
Dividends received
-
-
2.5
Other
-
-
2.6
Net cash from / (used in) investing
activities
(823)
(1,698)
3.
Cash flows from financing activities
3.1
Proceeds from issues of equity securities
(excluding convertible debt securities)
-
-
2.2
Proceeds from disposal of:
3.2
Proceeds from issue of convertible debt
securities
-
-
3.3
Proceeds from exercise of options
-
-
3.4
Transaction costs related to issues of
equity securities or convertible debt
securities
-
-
3.5
Proceeds from borrowings
-
7,500
3.6
Repayment of borrowings
(257)
(415)
3.7
Transaction costs related to loans and
borrowings
-
-
3.8
Dividends paid
-
-
3.9
Other (provide details if material)
-
-
3.10
Net cash from / (used in) financing
activities
(257)
7,085
4.
Net increase / (decrease) in cash and
cash equivalents for the period
4.1
Cash and cash equivalents at beginning of
period
8,793
5,406
(1,454)
(4,524)
(823)
(1,698)
4.2
Net cash from / (used in) operating
activities (item 1.9 above)
4.3
Net cash from / (used in) investing activities
(item 2.6 above)
7|Page
Consolidated statement of cash flows
Current quarter
£’000
Year to date
(6 months)
£’000
4.4
Net cash from / (used in) financing activities
(item 3.10 above)
(257)
7,085
4.5
Effect of movement in exchange rates on
cash held
(17)
(27)
4.6
Cash and cash equivalents at end of
period
6,242
6,242
5.
Reconciliation of cash and cash
equivalents
Current quarter
£’000
Previous quarter
£’000
at the end of the quarter (as shown in the
consolidated statement of cash flows) to the
related items in the accounts
5.1
Bank balances
6,242
8,793
5.2
Call deposits
-
-
5.3
Bank overdrafts
-
-
5.4
Other (provide details)
-
-
5.5
Cash and cash equivalents at end of
quarter (should equal item 4.6 above)
6,242
8,793
6.
Payments to related parties of the entity and their
associates
6.1
Aggregate amount of payments to related parties and their
associates included in item 1
91
6.2
Aggregate amount of payments to related parties and their
associates included in item 2
-
Current quarter
£'000
Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an
explanation for, such payments.
8|Page
7.
Financing facilities
Note: the term “facility’ includes all forms of financing
arrangements available to the entity.
Add notes as necessary for an understanding of the
sources of finance available to the entity.
Total facility
amount at quarter
end
£’000
Amount drawn at
quarter end
£’000
7,500
7,500
7.1
Loan facilities
7.2
Credit standby arrangements
-
-
7.3
Other (please specify)
-
-
7.4
Total financing facilities
-
7,500
7.5
Unused financing facilities available at quarter end
7.6
Include in the box below a description of each facility above, including the lender, interest
rate, maturity date and whether it is secured or unsecured. If any additional financing
facilities have been entered into or are proposed to be entered into after quarter end,
include a note providing details of those facilities as well.
-*
The loan facility is as announced by the Company on 12 December 2022:
https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/292402611642-2A1419999?access_token=83ff96335c2d45a094df02a206a39ff4.
The lender is AXA PPP Healthcare Group Limited (AXA).
The interest is 5%, accruing quarterly and payable in full on the Maturity Date. The loan is
guaranteed by Doctor Care Anywhere Group Limited (DOC) and a number of its
subsidiaries. To secure the loan, the subsidiaries have granted AXA a debenture creating
fixed and floating charges over all their assets and undertaking and DOC has granted AXA
a pledge over all its shares in the subsidiaries.
Maturity date is 30 November 2026.
*Tranche 3 of the Loan Facility of £2.5M was drawn down in July 2023. If this tranche had
been drawn down in Q2 2023, the estimated quarters of funding per Note 8.5 below would
have been extended to 6.
£’000
8.
Estimated cash available for future operating activities
8.1
Net cash from / (used in) operating activities (item 1.9)
(1,454)
8.2
Cash and cash equivalents at quarter end (item 4.6)
6,242
8.3
Unused finance facilities available at quarter end (item 7.5)
8.4
Total available funding (item 8.2 + item 8.3)
8.5
Estimated quarters of funding available (item 8.4 divided by
item 8.1)
6,242
4
Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as “N/A”. Otherwise, a
figure for the estimated quarters of funding available must be included in item 8.5.
8.6
If item 8.5 is less than 2 quarters, please provide answers to the following questions:
8.6.1
Does the entity expect that it will continue to have the current level of net operating
cash flows for the time being and, if not, why not?
Answer:
9|Page
8.6.2
Has the entity taken any steps, or does it propose to take any steps, to raise further
cash to fund its operations and, if so, what are those steps and how likely does it
believe that they will be successful?
Answer:
8.6.3
Does the entity expect to be able to continue its operations and to meet its business
objectives and, if so, on what basis?
Answer:
Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.
10 | P a g e
Compliance statement
1
This statement has been prepared in accordance with accounting standards and policies which
comply with Listing Rule 19.11A.
2
This statement gives a true and fair view of the matters disclosed.
Date: 20 July 2023
Authorised by: Board of Directors
11 | P a g e
Share your feedback
Discover